Focus is turning to the development of peptide analogues of antibody-derived radiotherapeutics, according to Dr Dave Madge. GlobalData. Potential for peptides to replace antibodies in radiopharma, ...

GNX201 is an anti-TACA pro-antibody that applies PrecisemAb Biotech's proprietary "Antibody Lock" technology, by fusing a masking peptide to the variable region of the anti-TACA mAb via a ...

A study in Chemistry A European Journal reveals that reduced MUC1 antigen density on gold nanoparticles still elicits potent tumor-specific immune responses, supporting flexible cancer vaccine design ...

Cancer treatments often struggle with balancing efficacy and side effects. A new study by EPFL scientists offers a promising solution using antibody-peptide inhibitor conjugates to target specific ...

Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins. Nature Chemical Biology , 2024; DOI: 10.1038/s41589-024-01627-z Cite This Page : ...

Amid the boom in the radiopharmaceutical space, peptide-based therapeutics could be set to outmanoeuvre antibody-based counterparts, according to WuXi AppTec’s discovery services vice-president ...

NEW TAIPEI CITY, Taiwan, May 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed ...

GNX201 is an anti-TACA pro-antibody that applies PrecisemAb Biotech's proprietary "Antibody Lock" technology, by fusing a masking peptide to the variable region of the anti-TACA mAb via a ...